Report Overview
Global Lacrimal Devices Market size is expected to be worth around US$ 216.4 Million by 2035 from US$ 133.1 Million in 2025, growing at a CAGR of 5.0% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 44.7% share with a revenue of US$ 59.5 Million.
The global Lacrimal Devices Market is witnessing steady growth, driven by the rising prevalence of dry eye syndrome, increasing incidence of lacrimal drainage disorders, and growing demand for minimally invasive ophthalmic treatments. Lacrimal devices, including plugs, stents, intubation sets, and cannulas, play a critical role in managing tear drainage abnormalities and improving ocular health outcomes. Advancements in ophthalmic technology, coupled with increasing awareness regarding eye care, are further supporting market expansion.
The market was valued at approximately US$ 133.1 million in 2025 and is projected to reach around US$ 216.4 million by 2035, registering a CAGR of 5.0% during the forecast period. The growing burden of age-related eye disorders and the increasing adoption of outpatient ophthalmic procedures are expected to create significant growth opportunities for market participants.
Among product categories, lacrimal plugs continue to account for a substantial share of market revenue due to their effectiveness in treating dry eye conditions. Silicone-based devices remain highly preferred owing to their superior biocompatibility, flexibility, and patient comfort. Dry eye syndrome represents the leading application segment, reflecting the rising global incidence of the condition. North America currently dominates the market, supported by advanced healthcare infrastructure, favorable reimbursement frameworks, and a strong presence of leading ophthalmic device manufacturers. Ongoing product innovations and expanding access to specialized eye care services are anticipated to further drive market growth in the coming years.
Click here for more information:([ https://market.us/report/lacrimal-devices-market/])
Key Takeaways
- The global Lacrimal Devices Market was valued at US$ 133.1 million in 2025 and is projected to reach approximately US$ 216.4 million by 2035, reflecting sustained market expansion over the forecast period.
- The market is anticipated to register a CAGR of 5.0% between 2026 and 2035, driven by increasing demand for effective lacrimal drainage and dry eye treatment solutions.
- Based on product type, Lacrimal Plugs emerged as the leading segment, capturing 38.6% of the total market share in 2025.
- In terms of material, Silicone held the dominant position with a 43.1% market share in 2025, owing to its excellent biocompatibility, flexibility, durability, and enhanced patient comfort.
- By application, Dry Eye Syndrome represented the largest segment, accounting for 45.9% of the global market revenue in 2025, highlighting the growing prevalence of the condition worldwide.
- Among end users, Ambulatory Surgical Centers (ASCs) maintained a leading position, contributing 35.8% of the market share in 2025 due to the increasing preference for outpatient ophthalmic procedures.
- North America remained the dominant regional market in 2025, securing more than 44.7% of the global market share and generating revenues of approximately US$ 59.5 million.
Key Market Segments
By Product Type
Lacrimal Stents
Lacrimal Plugs
Lacrimal Tubes
Saccal Dilators
Intubation Sets
Others
By Material
Silicone
Polyurethane
Metal
Others
By Application
Dry Eye Syndrome
Epiphora
Lacrimal Canalicular Stenosis
Blocked Tear Duct
Others
By End User
Hospitals
Ambulatory Surgical Centers
Specialty Ophthalmic Clinics
Market Key Players
Beaver-Visitec International, Inc. (BVI)
FCI Ophthalmics
Lacrimedics, Inc.
Medtronic plc
Bess Medizinprodukte GmbH
Cook Medical, Inc.
Surgical Specialties Corporation
Kaneka Corporation
Odyssey Medical, Inc.
Aurolab
OptiMed Medizinische Instrumente GmbH
Rumex International Corporation
Molteno Ophthalmic Ltd
MicroSurgical Technology
Labtician Ophthalmics, Inc.
Others
Driver:
The increasing prevalence of dry eye disease is a major factor driving demand for lacrimal devices worldwide. Dry eye syndrome is one of the most common ocular disorders and often requires interventions such as punctal plugs and lacrimal stents to improve tear retention and ocular surface health. According to the National Eye Institute (NEI), nearly 16.4 million adults in the United States have been diagnosed with dry eye disease, while millions more experience symptoms without a formal diagnosis. The condition is particularly prevalent among older adults and women. Furthermore, global population aging is accelerating, creating a larger patient pool susceptible to age-related ocular disorders. The World Health Organization (WHO) estimates that the number of people aged 60 years and older will increase from 1 billion in 2020 to 1.4 billion by 2030, reaching 2.1 billion by 2050. As tear production naturally declines with age, the growing elderly population is expected to increase the incidence of lacrimal system disorders. This demographic shift is driving greater adoption of lacrimal devices across hospitals, ophthalmology clinics, and ambulatory surgical centers.
Trend
A significant trend shaping the lacrimal devices market is the increasing preference for minimally invasive ophthalmic treatments. Patients and healthcare providers are increasingly opting for procedures that reduce surgical trauma, recovery time, and healthcare costs while delivering effective outcomes. Punctal plugs, canalicular stents, and other lacrimal implants have gained popularity as alternatives to more invasive surgical interventions for managing dry eye syndrome and lacrimal drainage disorders. Healthcare systems worldwide are also emphasizing outpatient care and same-day procedures, supporting the adoption of these devices in ambulatory settings. The National Eye Institute identifies tear duct plugs as a commonly recommended treatment when tears drain too rapidly from the eye, demonstrating growing clinical acceptance of device-based management strategies. Additionally, technological advancements in silicone and bioresorbable materials are improving patient comfort, device retention, and treatment outcomes. As healthcare providers continue to prioritize patient-centric care and minimally invasive solutions, demand for advanced lacrimal devices is expected to expand steadily. This trend is particularly evident in developed healthcare markets where ophthalmic care infrastructure and awareness levels remain high.
Restraint:
Despite favorable clinical benefits, the lacrimal devices market faces challenges due to the underdiagnosis and limited awareness of lacrimal disorders. Dry eye disease and tear drainage abnormalities often remain undetected, especially in their early stages, because symptoms are frequently mistaken for temporary irritation, fatigue, or environmental discomfort. According to the National Eye Institute, dry eye affects millions of individuals annually, yet a substantial proportion of cases remain undiagnosed or untreated. Many patients rely on over-the-counter eye drops rather than seeking specialized ophthalmic evaluation, reducing the utilization of advanced lacrimal devices. Additionally, access to trained ophthalmologists and specialized eye care services remains uneven across many low- and middle-income countries. Cost considerations also act as a barrier, particularly in regions where reimbursement coverage for ophthalmic devices is limited. The need for procedural expertise and follow-up monitoring can further restrict adoption in smaller healthcare facilities. These factors collectively slow the penetration of lacrimal devices, particularly in emerging markets where awareness of advanced treatment options for dry eye and lacrimal obstruction remains relatively low compared with developed regions.
Opportunity:
Expanding ophthalmic healthcare infrastructure in emerging economies presents a substantial growth opportunity for the lacrimal devices market. Governments and healthcare organizations are investing heavily in improving access to eye care services to address the growing burden of vision-related disorders. At the same time, demographic changes are increasing the need for specialized ophthalmic treatments. According to the WHO, by 2030, one in every six people globally will be aged 60 years or older, significantly increasing the population at risk of dry eye disease and lacrimal system disorders. In countries such as India, the elderly population continues to grow rapidly, with WHO data indicating that the country already had approximately 104 million people aged 60 years and above. Rising healthcare expenditure, improving diagnostic capabilities, and greater awareness of eye health are encouraging earlier diagnosis and treatment of ocular conditions. Furthermore, the expansion of ambulatory surgical centers and specialized ophthalmology clinics is creating additional channels for lacrimal device adoption. Manufacturers that focus on affordable, patient-friendly, and technologically advanced products are likely to benefit from the increasing demand for eye care solutions across developing healthcare markets.
Conclusion: The global Lacrimal Devices Market is poised for steady growth over the forecast period, supported by the increasing prevalence of dry eye syndrome, rising incidence of lacrimal drainage disorders, and expanding geriatric population. Growing adoption of minimally invasive ophthalmic procedures, coupled with advancements in biocompatible materials and device technologies, is further enhancing market prospects. While challenges such as underdiagnosis and limited access to specialized eye care may restrain growth in certain regions, ongoing investments in healthcare infrastructure and ophthalmic services are expected to create significant opportunities. As awareness of ocular health continues to rise, demand for innovative lacrimal devices is likely to strengthen globally.
Top comments (0)